Duaklir Pressair is a drug owned by Covis Pharma Gmbh. It is protected by 12 US drug patents filed from 2019 to 2021. Out of these, 3 drug patents are active and 9 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 13, 2029. Details of Duaklir Pressair's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| USRE46417 | Quinuclidine derivatives and their use as muscarinic M3 receptor ligands |
Feb, 2025
(2 months ago) |
Expired
|
| US7078412 | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) |
Expired
|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10085974 | Dosage and formulation |
Mar, 2029
(3 years from now) | Active |
| US11000517 | Dosage and formulation |
Mar, 2029
(3 years from now) | Active |
| US8051851 | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
Apr, 2027
(1 year, 11 months from now) | Active |
| US6681768 | Powder formulation disintegrating system and method for dry powder inhalers |
Aug, 2022
(2 years ago) |
Expired
|
| US9056100 | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) |
Expired
|
| US7750023 | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) |
Expired
|
| US10034867 | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) |
Expired
|
| US9333195 | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) |
Expired
|
| US10588895 | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) |
Expired
|
| US8129405 | Quinuclidine derivatives and medicinal compositions containing the same |
Jul, 2020
(4 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Duaklir Pressair's patents.
Latest Legal Activities on Duaklir Pressair's Patents
Given below is the list of recent legal activities going on the following patents of Duaklir Pressair.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 17 Jun, 2024 | US9333195 |
| Expire Patent Critical | 22 Apr, 2024 | US10588895 |
| Expire Patent Critical | 08 Apr, 2024 | US8129405 |
| Maintenance Fee Reminder Mailed Critical | 01 Jan, 2024 | US9333195 |
| Maintenance Fee Reminder Mailed Critical | 06 Nov, 2023 | US10588895 |
| Maintenance Fee Reminder Mailed Critical | 23 Oct, 2023 | US8129405 |
| Expire Patent Critical | 24 Jul, 2023 | US9056100 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Apr, 2023 | US8051851 |
| Maintenance Fee Reminder Mailed Critical | 06 Feb, 2023 | US9056100 |
| Expire Patent Critical | 05 Sep, 2022 | US10034867 |
FDA has granted several exclusivities to Duaklir Pressair. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Duaklir Pressair, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Duaklir Pressair.
Exclusivity Information
Duaklir Pressair holds 1 exclusivities. All of its exclusivities have expired in 2022. Details of Duaklir Pressair's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Mar 29, 2022 |
Several oppositions have been filed on Duaklir Pressair's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Duaklir Pressair's generic, the next section provides detailed information on ongoing and past EP oppositions related to Duaklir Pressair patents.
Duaklir Pressair's Oppositions Filed in EPO
Duaklir Pressair has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 06, 2016, by Hexal Ag. This opposition was filed on patent number EP09719213A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP09719213A | May, 2016 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP09719213A | May, 2016 | Hexal AG | Granted and Under Opposition |
US patents provide insights into the exclusivity only within the United States, but Duaklir Pressair is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Duaklir Pressair's family patents as well as insights into ongoing legal events on those patents.
Duaklir Pressair's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Duaklir Pressair's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 13, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Duaklir Pressair Generics:
There are no approved generic versions for Duaklir Pressair as of now.
Alternative Brands for Duaklir Pressair
Duaklir Pressair which is used for managing and maintaining chronic obstructive pulmonary disease (COPD)., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Covis |
| |||
About Duaklir Pressair
Duaklir Pressair is a drug owned by Covis Pharma Gmbh. It is used for managing and maintaining chronic obstructive pulmonary disease (COPD). Duaklir Pressair uses Aclidinium Bromide; Formoterol Fumarate as an active ingredient. Duaklir Pressair was launched by Covis in 2019.
Approval Date:
Duaklir Pressair was approved by FDA for market use on 29 March, 2019.
Active Ingredient:
Duaklir Pressair uses Aclidinium Bromide; Formoterol Fumarate as the active ingredient. Check out other Drugs and Companies using Aclidinium Bromide; Formoterol Fumarate ingredient
Treatment:
Duaklir Pressair is used for managing and maintaining chronic obstructive pulmonary disease (COPD).
Dosage:
Duaklir Pressair is available in powder, metered form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.4MG/INH;0.012MG/INH | POWDER, METERED | Prescription | INHALATION |